Subclinical cardiovascular disease parameters after one year in new users of depot medroxyprogesterone acetate compared to copper-IUD

Author(s)

Cursino, Kleber ^[1] ; de Lima, Gabriel Araujo ^[1] ; Silva dos Santos, Priscilla de Nazare ^[1] ; Pavin, Elizabeth Joao ^[2] ; Bahamondes, Luis ^[1] ; Fernandes, Arlete ^[1]

Affiliation

^[1] Univ Estadual Campinas, Med Sch, Family Planning Clin, Dept Obstet & Gynecol, Campinas, SP - Brazil

^[2] Univ Estadual Campinas, Dept Clin Med, Med Sch, Campinas, SP - Brazil

• Document type: Journal article
• Source: EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE; v. 23, n. 3, p. 201-206, 2018.
• Web of Science Citations: 0

Abstract

Purpose: To evaluate markers of cardiovascular disease in women with normal insulin sensitivity who had recently initiated use of depot medroxyprogesterone acetate (DMPA) as a contraceptive. Materials and methods: A prospective, non-randomised, comparative study. Data of 30 women of 18-40 years of age, with normal hyperinsulinaemic-euglycaemic clamp at baseline and body mass index (BMI) < 30, who opted to use DMPA or a copper intrauterine device (IUD) as a contraceptive, were analysed. Serum samples were collected for evaluation of the lipid and hepatic profile, C-reactive protein, TNF-alpha, interleukin-6, leptin/adiponectin ratio and free fatty acids; body composition was evaluated using DXA, blood pressure and carotid intima-media thickness were measured. Evaluations were performed at baseline and 12 months later. The groups were compared using repeated measures analysis of variance (ANOVA). Significance level was 5%. Results: The mean age of the women in the DMPA and IUD group was 28.76.5 and 28.3 +/- 5.8 years, respectively; the BMI was 23.0 +/- 3.4 and 24.3 +/- 2.7 kg/m(2), respectively, in the same groups. At 12 months, triglyceride levels were higher in the DMPA group compared to the IUD group and there was an increase in apolipoprotein B-100 in relation to baseline in DMPA group; there were no other difference between the groups. Conclusions: No clinical cardiovascular effect was found but deterioration in CV markers was observed in the first year of use of DMPA. (AU)

• FAPESP's process: 09/53293-0 - Prospective study for evaluation of the insulin resistance, lipid metabolism and sub clinical cardiovascular disease in women who initiate the depot-medroxyprogesterone acetate (DMP A) contraceptive method with in follow-up for two years. (Project of scientific research)
• Grantee: Luis Guillermo Bahamondes
• Support Opportunities: Research Grants - Research in Public Policies for the National Health Care System (PP-SUS)